CAS Medical Systems granted Japanese patent for LASER-SIGHT technology in FORE-SIGHT Oximeter

NewsGuard 100/100 Score

CAS Medical Systems, Inc. (Nasdaq:CASM) today announced that that the Japanese Patent Office has granted a new patent for the Company's LASER-SIGHT® technology used in the FORE-SIGHT® Oximeter.

The newly granted patent (JP 4,465,271), entitled "Method for spectrophotometric blood oxygenation monitoring," includes 28 claims broadly covering methods for non-invasively determining biological tissue oxygenation in general, and for non-invasive methods utilizing near-infrared spectroscopy (NIRS) techniques in particular, including:

  • a method for non-invasively determining the absolute oxygen saturation value within biological tissue;
  • a method that provides calibration means to account for energy losses due to scattering as well as other background absorption from biological compounds; and
  • a method that can non-invasively determine oxygen saturation within tissue at certain depth that limits the influence from the superficial tissues.  

"We are very pleased with the grant of this first FORE-SIGHT related patent in Japan, which further extends CASMED's leadership on intellectual property for absolute oximetry measurements," said Andrew Kersey, President and Chief Executive Officer of CASMED. "Japan is known for having a rigorous approval process for patents, and this will offer us protection on our invention and intellectual property in this country.

"The patent reflects many years of research and development focused on bringing to market a non-invasive, commercially viable technology that allows clinicians to monitor absolute levels of oxygen saturation in the brain and other body tissues. Our goal is to continue to pursue the issuance of patents to enable us to maximize the value of the innovative technology used in this compelling device."

Source CAS Medical Systems, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates